Literature DB >> 14633883

Effect of anticoagulants and storage temperature on the stability of receptor activator for nuclear factor-kappa B ligand and osteoprotegerin in plasma and serum.

Benjamin Y Y Chan1, Katherine A Buckley, Brian H Durham, James A Gallagher, William D Fraser.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14633883     DOI： 10.1373/clinchem.2003.023747

Source DB:  PubMed          Journal:  Clin Chem        ISSN： 0009-9147            Impact factor:   8.327


× No keyword cloud information.
  11 in total

1.  The sex-specific association of serum osteoprotegerin and receptor activator of nuclear factor kappaB legend with bone mineral density in older adults: the Rancho Bernardo study.

Authors:  Anna Stern; Gail A Laughlin; Jaclyn Bergstrom; Elizabeth Barrett-Connor
Journal:  Eur J Endocrinol       Date:  2007-05       Impact factor: 6.664

2.  Variations along the 24-hour cycle of circulating osteoprotegerin and soluble RANKL: a rhythmometric analysis.

Authors:  A Dovio; D Generali; M Tampellini; A Berruti; S Tedoldi; M Torta; S Bonardi; M Tucci; G Allevi; S Aguggini; A Bottini; L Dogliotti; A Angeli
Journal:  Osteoporos Int       Date:  2007-08-17       Impact factor: 4.507

3.  Correlation of plasma osteoprotegerin (OPG) and receptor activator of the nuclear factor κB ligand (RANKL) levels with clinical risk factors in patients with advanced carotid atherosclerosis.

Authors:  Constantinos Giaginis; Aikaterini Papadopouli; Athina Zira; Athanasios Katsargyris; Christos Klonaris; Stamatios Theocharis
Journal:  Med Sci Monit       Date:  2012-10

Review 4.  Osteoprotegerin in Cardiometabolic Disorders.

Authors:  C Pérez de Ciriza; A Lawrie; N Varo
Journal:  Int J Endocrinol       Date:  2015-05-11       Impact factor: 3.257

5.  High circulating osteoprotegerin levels are associated with non-zero blood groups.

Authors:  Elod Erno Nagy; Timea Varga-Fekete; Attila Puskas; Piroska Kelemen; Zoltan Brassai; Katalin Szekeres-Csiki; Timea Gombos; Maria Csilla Csanyi; Jolan Harsfalvi
Journal:  BMC Cardiovasc Disord       Date:  2016-05-26       Impact factor: 2.298

6.  Effect of Osteoprotegerin and Dickkopf-Related Protein 1 on Radiological Progression in Tightly Controlled Rheumatoid Arthritis.

Authors:  Carmen Gómez-Vaquero; Irene Martín; Estibaliz Loza; Loreto Carmona; José Ivorra; José Antonio Narváez; Javier Hernández-Gañán; Pedro Alía; Javier Narváez
Journal:  PLoS One       Date:  2016-12-02       Impact factor: 3.240

7.  Osteoprotegerin concentration and risk of cardiovascular outcomes in nine general population studies: Literature-based meta-analysis involving 26,442 participants.

Authors:  Lena Tschiderer; Johann Willeit; Georg Schett; Stefan Kiechl; Peter Willeit
Journal:  PLoS One       Date:  2017-08-24       Impact factor: 3.240

8.  Perturbations of circulating levels of RANKL-osteoprotegerin axis in relation to lipids and progression of atherosclerosis in HIV-infected and -uninfected adults: ACTG NWCS 332/A5078 Study.

Authors:  Theodoros Kelesidis; Michelle A Kendall; Otto O Yang; Howard Hodis; Judith S Currier
Journal:  AIDS Res Hum Retroviruses       Date:  2013-02-25       Impact factor: 1.723

Review 9.  Role of RANKL-RANK/osteoprotegerin pathway in cardiovascular and bone disease associated with HIV infection.

Authors:  Theodoros Kelesidis; Judith S Currier; Otto O Yang; Todd T Brown
Journal:  AIDS Rev       Date:  2014 Jul-Sep       Impact factor: 2.381

Review 10.  Osteoprotegerin (OPG) as a biomarker for diabetic cardiovascular complications.

Authors:  Mette Bjerre
Journal:  Springerplus       Date:  2013-12-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.